Blueprint Medicines stock hits all-time high at 128.34 USD

June 23, 2025 12:11 PM PDT | By EODHD

Google News:

Blueprint Medicines stock hits all-time high at 128.34 USD — Image source: Kalkine Media

Recent News

RTX (NYSE:RTX) Stands Out Amid Liabilities Dow Jones Industrial Averag...

Renasant (NYSE:RNST) Stock Shows Institutional Strength Russell 1000

Allison Transmission (NYSE:ALSN) Stock Surges Ahead Of S&P 500

CRH plc (NYSE:CRH) Stock Dominated S&P 500

Blueprint Medicines Corp (NASDAQ:BPMC) stock reached a significant milestone, hitting an all-time high of 128.34 USD. According to InvestingPro analysis, the stock appears overvalued at current levels, with technical indicators suggesting overbought conditions. This achievement reflects a robust performance, with the stock delivering impressive returns of 47% year-to-date and a 23% gain over the past year. The biotechnology firm’s stock has been on an upward trajectory, buoyed by advancements in its therapeutic offerings and strategic initiatives. With a remarkable revenue growth of 99% and a healthy current ratio of 2.8, the company maintains strong liquidity.

The latest high underscores investor confidence in Blueprint Medicines’ growth potential and market position in the competitive biotech sector. InvestingPro subscribers can access 12 additional key insights about BPMC’s financial health and growth prospects through the comprehensive Pro Research Report. In other recent news, Blueprint Medicines has announced its acquisition by Sanofi (NASDAQ:SNY) in a deal valued at approximately $9.5 billion. The acquisition includes a cash payment of $129 per share and contingent value rights tied to the pipeline asset BLU-808. This strategic move aims to expand Sanofi’s portfolio in rare immunological diseases and enhance its capabilities in precision medicine.

The acquisition is expected to be finalized in the third quarter of 2025, pending regulatory approvals. Following the announcement, Citi analysts upgraded Blueprint Medicines’ stock to Neutral, setting a price target of $129. Meanwhile, Citizens JMP downgraded the stock from Market Outperform to Market Perform, reflecting the anticipated changes post-acquisition. TD Cowen and JPMorgan also downgraded the stock, citing the acquisition’s impact on the stock’s performance and valuation. Blueprint Medicines’ recent earnings revealed net revenues of nearly $150 million in the first quarter of 2025, marking a growth of over 60% compared to the previous year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.